- $1.22bn
- $1.15bn
- $356.30m
- 69
- 23
- 41
- 41
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 125 | 149 | 213 | 281 | 356 |
Cost of Revenue | |||||
Gross Profit | 80.1 | 96.3 | 132 | 172 | 232 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 141 | 174 | 330 | 457 | 494 |
Operating Profit | -16.4 | -25.7 | -117 | -177 | -138 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.1 | -27.2 | -118 | -176 | -135 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.3 | -27.3 | -118 | -176 | -137 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.3 | -27.3 | -118 | -176 | -137 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -91.4 | -27.3 | -118 | -176 | -137 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.47 | -0.691 | -2.37 | -3.36 | -2.5 |